Barclays
AKTX

Barclays’s Akari Therapeutics AKTX Stock Holding History

Barclays’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-33
Closed -$114K – 7014
2017
Q4 		$114K Buy
+33
New +$127K ﹤0.01% 5143

Other funds holding AKTX

HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's AKTX Position: Q1 2018 in Review

Barclays sold out of Akari Therapeutics (AKTX) in Q1 2018, closing a stake of 33 shares — an estimated $114K sold.

Barclays first reported a position in AKTX in Q4 2017 and held it in 1 quarter. The position peaked at $114K in Q4 2017. 9 funds tracked by Wall St. Rank hold AKTX as of Q1 2018.

  • Barclays reported no remaining Akari Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Barclays sold 33 Akari Therapeutics shares in Q1 2018, an estimated $114K.
  • Barclays first reported a position in Akari Therapeutics in Q4 2017 and held it in 1 quarter.
  • Barclays's Akari Therapeutics position peaked at $114K in Q4 2017.
  • 9 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2018.

Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.